{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-033348","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.963040+00:00","generated_at":"2026-05-17T00:18:14.914242+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences Q3 2025 revenue $86k, GAAP net loss ($19.4M), cash $95.2M","bullets":["Revenue of $86k from limited market release of nPulse Vybrance system.","GAAP net loss ($19.4M) vs ($12.7M) in Q3 2024; Non-GAAP net loss ($13.5M) vs ($9.4M).","Cash $95.2M at Sep 30, 2025; operating cash burn $13.0M in Q3 2025.","Enrolled 40% of subjects in PRECISE-BTN thyroid nodule study; FDA IDE approved for NANOCLAMP AF surgical trial.","Treated 150 patients with nsPFA 360° catheter in European AF feasibility study; IDE submission filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-033348","json":"https://secwatch.observer/filing/0001437749-25-033348.json","markdown":"https://secwatch.observer/filing/0001437749-25-033348.md","text":"https://secwatch.observer/filing/0001437749-25-033348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925033348/0001437749-25-033348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925033348/plse20250826_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:18:14.914242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}